XHKG
0926
, Last price
HKD
Name
Besunyen Holdings Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Besunyen Holdings Company Limited, established in Beijing, China, in 2000, functions as a subsidiary of Foreshore Holding Group Limited. The company's core operations encompass the research, development, production, and distribution of therapeutic tea products and pharmaceutical goods throughout the People's Republic of China. Its product range includes a variety of therapeutic teas, prominently featuring the Besunyen brand, alongside specific offerings such as herbal tea, Besunyen Detox, and Besunyen slimming tea. Furthermore, functional teas, such as Besunyen Fit Tea, are also part of its portfolio. Within its pharmaceutical segment, Besunyen markets LARLLY Orlistat for weight loss and manufactures and sells over-the-counter (OTC) medications, including the Besunyen Orlistat weight-loss capsule. Its products reach consumers via an extensive distribution network that includes OTC pharmacies, retail locations in shopping centers and supermarkets, a network of distributors and sub-distributors, and various online e-commerce channels.
Key people
Yihong Zhao
Executive Chairman of the Board, Chief Executive Officer
Juan Wang
Chief Financial Officer · since 2013
Yuanhua Zhao
Chief Operating Officer · since 2014
Ruhai Lin
Vice President - public relationships, new products development and administrative functions
Jeiching Win
Vice President - New Business and New Products Overseas · since 2013
Hongjiang Yu
Vice President - Audit and Legal
Lap Ming Au
Company Secretary · since 2010
Yan Gao
Executive Vice Chairman of the Board
Non-Executive Director · since 2010
Non-Executive Director · since 2009
Non-Executive Independent Director · since 2019
Independent Non-Executive Director · since 2016
Independent Non-Executive Director · since 2010
Independent non-executive Directors · since 2014
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||